Kestra Medical Technologies (KMTS) vs PROCEPT BioRobotics (PRCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Kestra Medical Technologies (KMTS) has outperformed PROCEPT BioRobotics (PRCT) over the past year, losing 3.8% versus a loss of 17.3%. Kestra Medical Technologies is the larger company by market cap ($1.50 billion vs $1.42 billion), about 1.1 times the size. PROCEPT BioRobotics converts more of its revenue into profit, with a net margin of -31.0% versus -138.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KMTS | PRCT |
|---|---|---|
| Share price | $25.10 | $24.70 |
| Market cap | $1.50B | $1.42B |
| 1-day change | -5.75% | -4.08% |
| YTD return | -5.35% | -21.49% |
| 1-year return | -3.79% | -17.28% |
| 5-year return | — | -30.64% |
| EPS (TTM) | $-2.67 | $-2.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $95.13M | $308.05M |
| Revenue growth (YoY) | +59.03% | +37.22% |
| Net income (latest FY) | $-131.61M | $-95.57M |
| Gross margin | 51.37% | 63.70% |
| Operating margin | -141.64% | -33.71% |
| Net margin | -138.36% | -31.02% |
| 52-week high | $31.99 | $38.11 |
| 52-week low | $17.34 | $16.67 |
| Distance from 52-week high | -21.54% | -35.19% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +24.02% | -7.89% |
| Average volume | 418.09K | 1.31M |
| Shares outstanding | 59.56M | 57.54M |
| Employees | 443 | 888 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KMTS has outperformed PRCT by 13.5 percentage points over the past year.
- PROCEPT BioRobotics is more profitable, keeping -31.0 cents of every revenue dollar as net income versus -138.4 cents for Kestra Medical Technologies.
- Kestra Medical Technologies grew revenue faster in its latest fiscal year (+59.03% vs +37.22%).
About Kestra Medical Technologies
KMTS stock →Kestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company.
Health Care · Medical/Dental Instruments · 443 employees
About PROCEPT BioRobotics
PRCT stock →PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia.
Health Care · Medical/Dental Instruments · 888 employees
KMTS vs PRCT FAQ
Which is bigger, Kestra Medical Technologies or PROCEPT BioRobotics?
Kestra Medical Technologies (KMTS) is larger, with a market capitalization of $1.50B compared with $1.42B for PROCEPT BioRobotics (PRCT).
Which stock has performed better over the past year, KMTS or PRCT?
KMTS returned -3.79% over the past 12 months, compared with -17.28% for PRCT (price return, excluding dividends). Past performance does not predict future results.
Are Kestra Medical Technologies and PROCEPT BioRobotics in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.